Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Azilect Rasagiline mesylate Parkinson's disease Do not list Complete
Duodopa Levodopa / carbidopa Parkinson's disease Do not list Complete
Azilect Rasagiline mesylate Parkinson's disease N/A Complete
Neupro Rotigotine Parkinson's disease Do not list Complete
Kynmobi apomorphine hydrochloride Parkinson’s disease Reimburse with clinical criteria and/or conditions Complete
Neupro Rotigotine Parkinson’s disease List with clinical criteria and/or conditions Complete
Kynmobi apomorphine hydrochloride Parkinson’s Disease Withdrawn
Stalevo Carbidopa, levodopa and entacapone Parkinsons Disease List in a similar manner Complete
Empaveli pegcetacoplan Paroxysmal nocturnal hemoglobinuria Reimburse with clinical criteria and/or conditions Complete
Ultomiris ravulizumab Paroxysmal nocturnal hemoglobinuria Reimburse with clinical criteria and/or conditions Complete